# Osilodrostat in Patients With Hypertension Caused by Hypercortisolaemia Due to Cushing's Syndrome

> **NCT07247162** · PHASE4 · NOT_YET_RECRUITING · sponsor: **RECORDATI GROUP** · enrollment: 63 (estimated)

## Conditions studied

- Hypertension
- Hypercortisolemia
- Cushing Syndrome

## Interventions

- **DRUG:** Osilodrostat
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07247162
- **Lead sponsor:** RECORDATI GROUP
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08
- **Primary completion:** 2028-05
- **Final completion:** 2028-07
- **Target enrollment:** 63 (ESTIMATED)
- **Last updated:** 2025-12-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07247162

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07247162, "Osilodrostat in Patients With Hypertension Caused by Hypercortisolaemia Due to Cushing's Syndrome". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07247162. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*